Form 8-K · Current report
Vertex Pharmaceuticals 8-K, filed Oct 20, 2026
- Filed
- CIK
- 0000875320
- Accession no.
- 0000875320-26-000278
Summary
Vertex Pharmaceuticals appointed Daniel Brennan to its board of directors on October 20, 2026, increasing the board from ten to eleven members; Brennan also joined the Audit and Finance Committee and received a $400,000 restricted stock unit award vesting in October 2027.
Key points
- Vertex's board size increased from ten to eleven members with Brennan's appointment.
- Brennan joined the board's Audit and Finance Committee.
- Brennan was Boston Scientific's chief financial officer from January 2014 until his retirement in June 2025 and serves on the boards of Waters Corporation and Madrigal Pharmaceuticals.
- Brennan received a $400,000 restricted stock unit award upon joining the board, vesting in October 2027.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
From the filing
Item 5.02 Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”). In connection with the appointment of Mr. Brennan, the size of the Board was increased from ten to eleven members. Mr. Brennan also has joined our Audit and Finance Committee. Mr. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.